thalidomide has been researched along with Debility in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with multiple myeloma are generally older and vary in fitness levels, which may influence the clinical benefit of treatment." | 2.94 | A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. ( Attal, M; Belch, A; Boyle, E; Chen, WM; Costa, B; Dimopoulos, MA; Facon, T; Guo, S; Houck, V; Hulin, C; Kim, K; Leleu, X; Lorraine Chretien, M; Ludwig, H; Macro, M; Manier, S; Meuleman, N; Mohty, M; Moreau, P; Renwick, W; Rodriguez-Otero, P; Rose, C; Silvia Monzini, M; Sturniolo, M; Tempescul, A; Tinel, A; Yves Mary, J; Zamagni, E, 2020) |
| "In the last decades, treatment of multiple myeloma (MM) has greatly improved due to the introduction of novel agents, including proteasome inhibitors (PI) and immunomodulatory agents (IMiDs)." | 2.53 | Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in? ( Delforge, M; Kint, N, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Facon, T | 1 |
| Dimopoulos, MA | 1 |
| Meuleman, N | 1 |
| Belch, A | 1 |
| Mohty, M | 1 |
| Chen, WM | 1 |
| Kim, K | 2 |
| Zamagni, E | 1 |
| Rodriguez-Otero, P | 1 |
| Renwick, W | 1 |
| Rose, C | 1 |
| Tempescul, A | 1 |
| Boyle, E | 1 |
| Manier, S | 1 |
| Attal, M | 1 |
| Moreau, P | 1 |
| Macro, M | 1 |
| Leleu, X | 1 |
| Lorraine Chretien, M | 1 |
| Ludwig, H | 1 |
| Guo, S | 1 |
| Sturniolo, M | 1 |
| Tinel, A | 1 |
| Silvia Monzini, M | 1 |
| Costa, B | 1 |
| Houck, V | 1 |
| Hulin, C | 1 |
| Yves Mary, J | 1 |
| Lee, HS | 1 |
| Kim, SJ | 1 |
| Lee, JJ | 1 |
| Kim, I | 1 |
| Kim, JS | 1 |
| Eom, HS | 1 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Shin, HJ | 1 |
| Mun, YC | 1 |
| Kim, MK | 1 |
| Lim, SN | 1 |
| Choi, CW | 1 |
| Kang, HJ | 1 |
| Yoon, SS | 1 |
| Min, CK | 1 |
| Kint, N | 1 |
| Delforge, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.[NCT05527340] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| An Open Label, Multicenter, Phase 2, Pilot Study, Evaluating Early Treatment With Bispecific T-cell Redirectors (Teclistamab and Talquetamab) in the Frontline Therapy of Newly Diagnosed High-risk Multiple Myeloma[NCT05849610] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-11-30 | Recruiting | ||
| Isatuximab in Combination With Lenalidomide-Dexamethasone Compared to Lenalidomide-Dexamethasone in Elderly Patients (Aged ≥70 Years) With Newly Diagnosed Myeloma: a Randomized Phase II Study (SGZ-2019-12650)[NCT04891809] | Phase 2 | 198 participants (Anticipated) | Interventional | 2021-10-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for thalidomide and Debility
| Article | Year |
|---|---|
Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib | 2016 |
2 trials available for thalidomide and Debility